Risk Factors for Benign Prostatic Hyperplasia

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2008 Jun 4

PMID 18519012

Citations 4

Authors

Steven J Jacobsen

Affiliations

Soon will be listed here.

Abstract

This review summarizes recent findings regarding risk factors for benign prostatic hyperplasia (BPH), including new data on hormonal factors, growth factors, comorbid conditions and lifestyle, diet, and exercise as they relate to BPH. In addition, it addresses the design and measurement issues that influence the inference that can be drawn from those studies. Most of the population-based studies on BPH have provided only modest insight into risk factors for BPH. The relationships with circulating levels of steroid hormones and growth factors are still unclear, whereas the association between sexual function and BPH is fairly consistent. Whether this represents a cause and effect relationship or is due to some unobserved confounding factor remains uncertain. There are few data on lifestyle factors that may be amenable to intervention. As future studies aim to address these issues, they should be carried out with rigorous methods, bypassing as many of the methodologic shortcomings of past studies as possible.

Citing Articles

Causal Associations Between Lifestyle Habits and Risk of Benign Prostatic Hyperplasia: A Two-Sample Mendelian Randomization Study.

Jia F, Wei Z, Kong X, Mao Y, Yang Y J Gerontol A Biol Sci Med Sci. 2023; 79(1).

PMID: 37526403 PMC: 10733171. DOI: 10.1093/gerona/glad187.

Comparative RNA-sequencing analysis of the prostate in a mouse model of benign prostatic hyperplasia with bladder outlet obstruction.

Tang X, Liu Z, Ren J, Cao Y, Xia S, Sun Z Mol Cell Biochem. 2023; 478(12):2721-2737.

PMID: 36920576 PMC: 10628026. DOI: 10.1007/s11010-023-04695-2.

Zaichick V, Zaichick S Age (Dordr). 2013; 36(1):167-81.

PMID: 23852618 PMC: 3889912. DOI: 10.1007/s11357-013-9561-8.

GOLPH2 expression may serve as diagnostic marker in seminomas.

Fritzsche F, Kristiansen G, Riener M, Dietel M, Oelrich B BMC Urol. 2010; 10:4.

PMID: 20184749 PMC: 2843682. DOI: 10.1186/1471-2490-10-4.

References

McGreevy K, Hoel B, Lipsitz S, Bissada N, Hoel D . Racial and anthropometric differences in plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-3. Urology. 2005; 66(3):587-92. DOI: 10.1016/j.urology.2005.03.070. View

Lacey Jr J, Deng J, Dosemeci M, Gao Y, Mostofi F, Sesterhenn I . Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Int J Epidemiol. 2001; 30(2):341-9. DOI: 10.1093/ije/30.2.341. View

Oliver S, Barrass B, Gunnell D, Donovan J, Peters T, Persad R . Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(1):163-5. DOI: 10.1158/1055-9965.epi-03-0102. View

Roberts R, Lieber M, Jacobson D, Girman C, Jacobsen S . Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc. 2005; 80(6):759-64. DOI: 10.1016/S0025-6196(11)61530-9. View

OLeary M, Fowler F, Lenderking W, Barber B, Sagnier P, Guess H . A brief male sexual function inventory for urology. Urology. 1995; 46(5):697-706. DOI: 10.1016/S0090-4295(99)80304-5. View

Green J, Holden S, Bose P, George D, Bowsher W . An investigation into the relationship between prostate size, peak urinary flow rate and male erectile dysfunction. Int J Impot Res. 2002; 13(6):322-5. DOI: 10.1038/sj.ijir.3900761. View

Peehl D, Cohen P, Rosenfeld R . The role of insulin-like growth factors in prostate biology. J Androl. 1996; 17(1):2-4. View

Mochtar C, Kiemeney L, Laguna M, van Riemsdijk M, Barnett G, Debruyne F . Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005; 65(2):300-5. DOI: 10.1016/j.urology.2004.09.030. View

Stattin P, Kaaks R, Riboli E, Ferrari P, Dechaud H, Hallmans G . Circulating insulin-like growth factor-I and benign prostatic hyperplasia--a prospective study. Scand J Urol Nephrol. 2001; 35(2):122-6. DOI: 10.1080/003655901750170506. View

10.

BERKSON J . Limitations of the application of fourfold table analysis to hospital data. Biometrics. 2010; 2(3):47-53. View

11.

Joseph M, Wei J, Harlow S, Cooney K, Dunn R, Jaffe C . Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate. 2002; 53(4):322-9. DOI: 10.1002/pros.10154. View

12.

Roberts R, Jacobson D, Rhodes T, Klee G, Leiber M, Jacobsen S . Serum sex hormones and measures of benign prostatic hyperplasia. Prostate. 2004; 61(2):124-31. DOI: 10.1002/pros.20080. View

13.

Sarma A, Jaffe C, Schottenfeld D, Dunn R, Montie J, Cooney K . Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology. 2002; 59(3):362-7. DOI: 10.1016/s0090-4295(01)01546-1. View

14.

Lagiou P, Wuu J, Trichopoulou A, Hsieh C, Adami H, Trichopoulos D . Diet and benign prostatic hyperplasia: a study in Greece. Urology. 1999; 54(2):284-90. DOI: 10.1016/s0090-4295(99)00096-5. View

15.

Boyle P, Robertson C, Mazzetta C, KEECH M, Hobbs R, Fourcade R . The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int. 2003; 92(7):719-25. DOI: 10.1046/j.1464-410x.2003.04459.x. View

16.

Meigs J, Mohr B, Barry M, Collins M, McKinlay J . Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001; 54(9):935-44. DOI: 10.1016/s0895-4356(01)00351-1. View

17.

Chokkalingam A, Gao Y, Deng J, Stanczyk F, Sesterhenn I, Mostofi F . Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 2002; 52(2):98-105. DOI: 10.1002/pros.10096. View

18.

Weisman K, Larijani G, Goldstein M, Goldberg M . Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy. 2000; 20(4):383-6. DOI: 10.1592/phco.20.5.383.35053. View

19.

Gass R . Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002; 90(7):649-54. DOI: 10.1046/j.1464-410x.2002.03001.x. View

20.

Gades N, Jacobson D, Girman C, Roberts R, Lieber M, Jacobsen S . Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int. 2005; 95(4):549-53. DOI: 10.1111/j.1464-410X.2005.05337.x. View